DELSTRIGO

DELSTRIGO is a comprehensive, single-pill medication prescribed for the treatment of HIV-1 infection in adults who have not previously taken HIV-1 medications, or for those whose healthcare provider deems them eligible to switch from their current HIV-1 medications.

This medication may cause changes in body fat distribution, resulting in increased fat in the upper back and stomach areas, and decreased fat in the arms and legs.

Some of the common side effects of Delstrigo are abnormal dreams, difficulty sleeping, nightmares, depression, headaches, dizziness, drowsiness, coughing, an irritated or runny nose, nausea, diarrhea, abdominal pain, vomiting, hair loss, rashes, muscle disorders, fatigue, and fever.

The active ingredients in DELSTRIGO are doravirine, lamivudine, and tenofovir disoproxil fumarate. The inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and sodium stearyl fumarate.

The mechanism of action of Delstrigo involves a combination of three drugs: doravirine, lamivudine, and tenofovir disoproxil fumarate. Doravirine, a pyridinone non-nucleoside reverse transcriptase inhibitor, works by inhibiting the replication of HIV-1 through non-competitive inhibition of HIV-1 reverse transcriptase.

Hepatotoxicity was observed in 13% of patients taking doravirine, with only 1% or less experiencing elevations in serum aminotransferase levels exceeding 5 times the upper limit of normal.

No study has directly compared the effectiveness of Delstrigo and Atripla in achieving an undetectable viral load. However, a study of 728 patients found that 84% of those on Delstrigo achieved this goal in 48 weeks, compared to 80% of those on Atripla.

The fixed-dose combination, known as Atripla, received its initial approval in the United States in 2006 and in the European Union in late 2007. Additionally, several generic versions of the medication are currently accessible. However, due to insufficient demand, the branded version of Atripla will be discontinued by the end of 2021.

The price of a 30-tablet supply of Delstrigo oral tablets (100 mg-300 mg-300 mg) can vary, but it is typically around $2,697, depending on the pharmacy you choose.

Atripla is not typically recommended as the initial treatment for most individuals with HIV, according to current guidelines. This is due to the availability of newer therapies that may offer greater safety and efficacy for the majority of patients. Nevertheless, Atripla may be suitable for certain individuals, and it is ultimately up to your doctor to determine the most appropriate treatment for you.

Input: Atripla (efavirenz / emtricitabine / tenofovir)
Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
Emtricitabine / tenofovir alafenamide

Dosage Form(s) Available
Oral tablet
Oral tablet
Oral tablet

Brand Names
N/A
N/A
Descovy

Output:
Atripla is available in the form of an oral tablet.
Biktarvy is available in the form of an oral tablet.
Emtricitabine / tenofovir alafenamide is available in the form of an oral tablet.
Descovy is available in the form of an oral tablet.

Teva’s Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets have been approved by the FDA as a generic alternative to ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) tablets.

The observed differences were not statistically significant, indicating that both regimens have comparable effectiveness. In technical terms, Biktarvy is considered “non-inferior” to Triumeq.

Dovato is a medication that combines antiviral properties to inhibit the replication of the human immunodeficiency virus (HIV) within the body. It is primarily prescribed for the treatment of HIV, the virus responsible for causing acquired immunodeficiency syndrome (AIDS). However, it is important to note that Dovato does not provide a cure for HIV or AIDS.

Would you like to learn more about Dovato oral? It is a brand name drug, but there may be a generic version available. The average cost for a 30-day supply of Dovato, which includes 50-300MG tablets, is $5,521.20. However, you can purchase Dovato at a discounted price of $3,130.68 by using the NowPatient Rx Advantage Card. This will save you 43% off the original cost.

Approximately 84% of DOVATO prescriptions are priced at less than $10 per month, while the majority of the remaining prescriptions above $10 have an average cost of $32 per month.

You can save 23% off the average retail price of $3,572.20 for the most common version of Dovato by using a NowPatient Rx Advantage Card. With the coupon, you can get Dovato for as low as $2,735.64. Dovato, which contains DOLUTEGRAVIR and LAMIVUDINE, helps manage the symptoms of HIV infection by limiting the spread of HIV in the body.

The price of a 30-day supply of Dovato oral tablets (50 mg-300 mg) can vary depending on the pharmacy, but it is typically around $2,968.

While Dovato is not known to have any direct interactions with alcohol, it is important to note that consuming alcohol while taking Dovato may potentially exacerbate its side effects. Nausea, headache, and liver problems are some examples of side effects that may be intensified when alcohol is consumed alongside Dovato. If you have any concerns or inquiries regarding the consumption of alcohol while on Dovato, it is advisable to consult with your doctor.

Dovato is exclusively prescribed for adults, whereas Biktarvy can be prescribed for both adults and certain children. Although both are combination medications, they differ in their active ingredients. Dovato consists of dolutegravir and lamivudine.

Please inform us if you have any allergies to the HIV medicines contained in Dovato, such as dolutegravir or lamivudine, or any other medications. Additionally, please let us know if you have a history of liver problems, including hepatitis B virus infection (HBV) or hepatitis C virus infection (HCV).

Dovato has been proven to be equally effective as a 3-drug regimen for individuals who have not undergone HIV treatment previously. After 48 weeks, 91% of individuals on Dovato had undetectable levels (less than 50 copies per mL), while 93% of those on the 3-drug regimen achieved the same outcome.

The research revealed that after 96 weeks, 86% of participants achieved undetectable viral loads of less than 50 copies (compared to 89.5% of individuals who were on a three-drug combination of dolutegravir + TDF/FTC).

Drug-related adverse events (AEs) were reported in 3% (21 out of 716) of patients receiving DOVATO and in 4% (30 out of 717) of patients receiving DTG + TDF/FTC. The most common drug-related AEs reported were headache, nausea, diarrhea, and insomnia. Headache was reported by 3% (21 out of 716) of patients receiving DOVATO and by 4% (30 out of 717) of patients receiving DTG + TDF/FTC. Nausea was reported by 2% (14 out of 716) of patients receiving DOVATO and by 6% (40 out of 717) of patients receiving DTG + TDF/FTC. Diarrhea was reported by 2% (15 out of 716) of patients receiving DOVATO and by 3% (21 out of 717) of patients receiving DTG + TDF/FTC. Insomnia was reported by 2% (15 out of 716) of patients receiving DOVATO and by 3% (20 out of 717) of patients receiving DTG + TDF/FTC.

To take Delstrigo, it is recommended to take one tablet once a day at the same time each day, with or without food. The tablet should be swallowed whole. If you vomit within 2 hours of taking the tablet, take another one and then continue with the next dose as usual.

Some of the common side effects of Delstrigo are abnormal dreams, difficulty sleeping, nightmares, depression, headaches, dizziness, drowsiness, coughing, an irritated or runny nose, nausea, diarrhea, abdominal pain, vomiting, hair loss, rashes, muscle disorders, fatigue, and fever.

Delstrigo has demonstrated efficacy in managing HIV infection in both adults and adolescents aged 12 years and older. Furthermore, the majority of side effects associated with Delstrigo are mild.

Doravirine is classified as a non-nucleoside reverse transcriptase inhibitor (NNRTI), while lamivudine is classified as a nucleoside reverse transcriptase inhibitor (NRTI) and tenofovir is classified as a nucleotide reverse transcriptase inhibitor (NRTI).

To ensure proper usage, it is important to follow your healthcare provider’s instructions and take DELSTRIGO daily. Typically, DELSTRIGO is taken as a single pill, without any other HIV-1 medications, once a day at approximately the same time, with or without food.

DELSTRIGO is a once-daily pill that can be taken with or without food. It is important to take it at the same time every day. If you are also taking rifabutin while on DELSTRIGO, your healthcare provider will prescribe an extra dose of doravirine to ensure that you have enough of it in your bloodstream.

At week 48, 8-10% of participants experienced a weight gain of 10% or more, and this increased to 14-16% at week 96 (Fig. ).

While uncommon, depression can occur as a side effect of taking Biktarvy. The majority of participants in clinical trials did not report experiencing depression as a result of the medication. However, for those who did, the depression was generally mild. A small number of individuals did experience more severe depression, including thoughts of suicide.

DELSTRIGO, a three-drug combination of doravirine, lamivudine, and tenofovir disoproxil fumarate (TDF), was approved by the U.S. Food and Drug Administration (FDA) on August 30, 2018. This approval allows DELSTRIGO to be used as a complete regimen for the treatment of HIV-1 infection in adult patients who have not previously received antiretroviral treatment.

The price of a 30-tablet supply of Delstrigo oral tablets (100 mg-300 mg-300 mg) is approximately $2,697, varying depending on the pharmacy. Please note that these prices are for customers paying in cash and do not apply to insurance plans.

Some possible common side effects of ertugliflozin are vaginal odor, discharge, or itching; redness, itching, swelling, rash, discharge, or pain in the skin around the penis; and increased frequency of urination.

It is crucial to adhere to your prescribed treatment to prevent the HIV virus from mutating or changing due to low levels of medication in your bloodstream.

Biktarvy (bictegravir, tenofovir, and emtricitabine) typically begins to show results within the first 4 weeks, leading to a significant decrease in HIV viral load in the blood.

Both Biktarvy and Atripla contain a combination of anti-virals. Biktarvy contains bictegravir, emtricitabine and tenofovir alafenamide, while Atripla contains efavirenz, emtricitabine and tenofovir. Both brand-name medications are used for the treatment of HIV and both are taken orally. The effectiveness of Biktarvy and Atripla for the treatment of HIV will vary based on each individuals condition, and their response to treatment.

Both Biktarvy and Dovato contain a combination of anti-virals. Biktarvy contains bictegravir, emtricitabine and tenofovir alafenamide, while Dovato contains dolutegravir and lamivudine. Both brand-name medications are used for the treatment of HIV and both are taken orally. The effectiveness of Biktarvy and Dovato for the treatment of HIV will vary based on each individuals condition, and their response to treatment.

Both Biktarvy and Truvada are effective treatments for HIV. However, Biktarvy may have better patient compliance than Truvada, due to it being taken as a single-tablet.

Both Biktarvy and Dovato contain a combination of anti-virals. Biktarvy contains bictegravir, emtricitabine and tenofovir alafenamide, while Dovato contains dolutegravir and lamivudine. Both brand-name medications are used for the treatment of HIV and both are taken orally. The effectiveness of Biktarvy and Dovato for the treatment of HIV will vary based on each individuals condition, and their response to treatment.